A study of ARQ 197 in healthy volunteers to assess the pharmacokinetic (PK) profile in extensive and poor metabolizers as defined by cytochrome P450 2c19 (CYP [cytochrome] 2C19) genotype

Trial Profile

A study of ARQ 197 in healthy volunteers to assess the pharmacokinetic (PK) profile in extensive and poor metabolizers as defined by cytochrome P450 2c19 (CYP [cytochrome] 2C19) genotype

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2015

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Colorectal cancer; Gastric cancer; Germ cell and embryonal neoplasms; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ArQule
  • Most Recent Events

    • 21 Jun 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 21 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
    • 22 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top